

RECEIVED
1633

SEP 26 2002

TECH CENTER 1600/2900



September 18, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of S. Klein and B. Molino

Application No. 09/903,813

Filed July 12, 2001

Antithrombotic Azacycloalkanoyl Peptides and Pseudopeptides

(Atty. Docket No. P 24,448-D US1)

Group No. 1633
Examiner D. Lukton

8/3
10/1/02
CD

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on Wednesday, September 18, 2002

Diane M. Davis
Diane M. Davis

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 C.F.R. §1.111 TO EXAMINER'S ACTION, DATED JULY 10, 2002

Sir:

Please amend the above-identified application as follows.

In the Description

Please replace the paragraph commencing at page 2, line 8, with the following rewritten paragraph

B1

It has been observed that the presence of Arg-Gly-Asp (RGD) is necessary in fibrinogen, fibronectin, and von Willebrand factor for their interaction with the cell surface receptor (Ruosahti E., Pierschbacher, *Cell* 1986, 44, 517-18). Two other amino acid sequences also seem to take part in the platelet attachment function of fibrinogen, namely, the Gly-Pro-Arg sequence, and a dodecapeptide. Small